title: Low-grade glioma.
abstract: Low-grade gliomas are slower growing than their high-grade counterparts. They account for 10-20 % of all primary brain tumors. Median survival is between 4.7 and 9.8 years. The goal of treatment is to prolong overall survival while maintaining good quality of life (QOL). Recent data favors early surgical resection. EOR is associated with delayed tumor recurrence and improved survival. Additional therapy with chemotherapy or radiation is indicated in patients with high-risk features. Lower doses (between 45 and 50.4 Gy) have been shown to be as effective without adverse effects compared to higher doses. Recent trials have shown benefit in combining chemotherapy with radiation compared to radiation alone. The optimal chemotherapeutic regimen (PCV or temozolomide (TMZ)) remains unknown, although TMZ is easier to administer and better tolerated by patients. Novel molecular markers including 1p/19q chromosomal codeletion and isocitrate dehydrogenase 1 (IDH1) mutation have been correlated with treatment response and survival.
authors.affiliation: Department of Neurology, Northwestern University, 710 North Lake Shore Drive, Abbott Hall, 11th Floor, Chicago, IL, 60611, USA, pkumthek@nmff.org.
authors.forename: Priya
authors.initials: P
authors.lastname: Kumthekar
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Raizer
authors.forename: Simran
authors.initials: S
authors.lastname: Singh
mesh_terms: D001932:Brain Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005910:Glioma / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000235:genetics; D009154:Mutation; D060787:Neoplasm Grading; D011379:Prognosis
chemical_list: D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human